DNLI
Denali Therapeutics Inc
$14.96
Earnings Summary
Revenue | $0Mn |
Net Profits | $-119.47Mn |
Net Profit Margins | -Inf% |
Highlights
Denali Therapeutics Inc’s revenue fell -100% since last year same period to $0Mn in the Q4 2023. On a quarterly growth basis, Denali Therapeutics Inc has generated -100% fall in its revenue since last 3-months.
Denali Therapeutics Inc’s net profit fell -21.07% since last year same period to $-119.47Mn in the Q4 2023. On a quarterly growth basis, Denali Therapeutics Inc has generated -20.25% fall in its net profits since last 3-months.
Denali Therapeutics Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q4 2023. On a quarterly growth basis, Denali Therapeutics Inc has generated -Inf% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Denali Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.7 |
EPS Estimate Current Year | -0.7 |
Highlights
Denali Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.7 - a 12.5% jump from last quarter’s estimates.
Denali Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.7.
Key Ratios
Key ratios of the Denali Therapeutics Inc post its Q4 2023 earnings
Earning Per Share (EPS) | -0.86 |
Highlights
Denali Therapeutics Inc’s earning per share (EPS) fell -14.67% since last year same period to -0.86 in the Q4 2023. This indicates that the Denali Therapeutics Inc has generated -14.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2023-05-08 | -0.7 | -0.8 | -14.29% |
2023-08-08 | -0.68 | 1.3 | 291.18% |
2024-02-28 | -0.8 | -0.86 | -7.5% |
2023-11-07 | -0.8 | -0.72 | 10% |
₹0 US Stocks a/c Opening Fee